Valneva SE (FRA:AYJ)
2.784
+0.028 (1.02%)
Last updated: Jun 6, 2025
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M
Revenue Growth
+21.64%
P/S Ratio
2.48
Revenue / Employee
260.95K
Employees
713
Market Cap
461.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 107.35B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Energy AG | 37.44B |
Deutsche Börse AG | 5.95B |
Valneva SE News
- 2 days ago - Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 - Benzinga
- 2 days ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ - Wallstreet:Online
- 2 days ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 3 days ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 12 days ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 26 days ago - Valneva Provides Update on Recommended Use of IXCHIQ by Elderly Individuals in the United States - Wallstreet:Online
- 26 days ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire
- 4 weeks ago - Valneva SE (VALN) Q1 2025 Earnings Call Transcript - Seeking Alpha